Stemline Therapeutics Offers Top-Line Results from Lead-In Stage of Ongoing BPDCN Pivotal Trial: Says SL-401 Showed Multi-Cycle Safety, Efficacy
May 28, 2015 at 16:16 PM EDT
Stemline Therapeutics, Inc. (Nasdaq: STML) today announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial ...